BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, Okusaka T, Tamai T, Suzuki T, Hisai T, Hayato S, Okita K, Kumada H. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2017;52:512-519. [PMID: 27704266 DOI: 10.1007/s00535-016-1263-4] [Cited by in Crossref: 140] [Cited by in F6Publishing: 140] [Article Influence: 23.3] [Reference Citation Analysis]
Number Citing Articles
1 Furuse J, Ueno M, Ikeda M. Systemic therapy for hepatocellular carcinoma: current status and future perspectives. Jpn J Clin Oncol 2021:hyab108. [PMID: 34258616 DOI: 10.1093/jjco/hyab108] [Reference Citation Analysis]
2 Gottlieb A, Best J, Canbay A. Implications of Immunotherapy in Hepatobiliary Tumors. Visc Med 2019;35:18-26. [PMID: 31312646 DOI: 10.1159/000496755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Liu Z, Lin Y, Zhang J, Zhang Y, Li Y, Liu Z, Li Q, Luo M, Liang R, Ye J. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38:447. [PMID: 31684985 DOI: 10.1186/s13046-019-1412-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 15.7] [Reference Citation Analysis]
4 Kounis I, Lewin M, Laurent-Bellue A, Poli E, Coilly A, Duclos-Vallée JC, Guettier C, Adam R, Lerut J, Samuel D, Rosmorduc O. Advanced epithelioid hemangioendothelioma of the liver: could lenvatinib offer a bridge treatment to liver transplantation? Ther Adv Med Oncol 2022;14:17588359221086909. [PMID: 35340695 DOI: 10.1177/17588359221086909] [Reference Citation Analysis]
5 Zhang C, Yang M. The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3740. [PMID: 34359642 DOI: 10.3390/cancers13153740] [Reference Citation Analysis]
6 Jannin A, Penel N, Ladsous M, Vantyghem MC, Do Cao C. Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders. Crit Rev Oncol Hematol. 2019;141:23-35. [PMID: 31202955 DOI: 10.1016/j.critrevonc.2019.05.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
7 Fu Z, Li X, Zhong J, Chen X, Cao K, Ding N, Liu L, Zhang X, Zhai J, Qu Z. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. Hepatol Int 2021;15:663-75. [PMID: 33877527 DOI: 10.1007/s12072-021-10184-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wei X, Zhang T, Yao Y, Zeng S, Li M, Xiang H, Zhao C, Cao G, Li M, Wan R, Yang P, Yang J. Efficacy of Lenvatinib, a multitargeted tyrosine kinase inhibitor, on laser-induced CNV mouse model of neovascular AMD. Experimental Eye Research 2018;168:2-11. [DOI: 10.1016/j.exer.2017.12.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
9 Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, Anand AC, Bhangui P, Chawla YK, Datta Gupta S, Dixit VK, Duseja A, Kalra N, Kar P, Kulkarni SS, Kumar R, Kumar M, Madhavan R, Mohan Prasad VG, Mukund A, Nagral A, Panda D, Paul SB, Rao PN, Rela M, Sahu MK, Saraswat VA, Shah SR, Shalimar, Sharma P, Taneja S, Wadhawan M; INASL Task-Force on Hepatocellular Carcinoma. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol 2020;10:43-80. [PMID: 32025166 DOI: 10.1016/j.jceh.2019.09.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
10 Harris WP, Wong KM, Saha S, Dika IE, Abou-Alfa GK. Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers. Semin Oncol 2018;45:116-23. [PMID: 30348531 DOI: 10.1053/j.seminoncol.2018.03.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
11 Bolcaen J, Nair S, Driver CHS, Boshomane TMG, Ebenhan T, Vandevoorde C. Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma. Pharmaceuticals (Basel) 2021;14:626. [PMID: 34209513 DOI: 10.3390/ph14070626] [Reference Citation Analysis]
12 Gaspar N, Campbell-Hewson Q, Gallego Melcon S, Locatelli F, Venkatramani R, Hecker-Nolting S, Gambart M, Bautista F, Thebaud E, Aerts I, Morland B, Rossig C, Canete Nieto A, Longhi A, Lervat C, Entz-Werle N, Strauss SJ, Marec-Berard P, Okpara CE, He C, Dutta L, Casanova M. Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050). ESMO Open 2021;6:100250. [PMID: 34562750 DOI: 10.1016/j.esmoop.2021.100250] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kinoshita A, Hagiwara N, Osawa A, Akasu T, Matsumoto Y, Ueda K, Saeki C, Oikawa T, Koike K, Saruta M. Poor tolerability of lenvatinib in elderly patients ≥80 years old with hepatocellular carcinoma: A multicenter observational study. J Oncol Pharm Pract 2022;:10781552221077039. [PMID: 35112972 DOI: 10.1177/10781552221077039] [Reference Citation Analysis]
14 Berdelou A, Borget I, Godbert Y, Nguyen T, Garcia ME, Chougnet CN, Ferru A, Buffet C, Chabre O, Huillard O, Leboulleux S, Schlumberger M. Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice. Thyroid 2018;28:72-8. [PMID: 29048237 DOI: 10.1089/thy.2017.0205] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 8.6] [Reference Citation Analysis]
15 Tomonari T, Sato Y, Tanaka H, Tanaka T, Fujino Y, Mitsui Y, Hirao A, Taniguchi T, Okamoto K, Sogabe M, Miyamoto H, Muguruma N, Kagiwada H, Kitazawa M, Fukui K, Horimoto K, Takayama T. Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array. Oncotarget 2020;11:2531-42. [PMID: 32655838 DOI: 10.18632/oncotarget.27640] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Motzer RJ, Taylor MH, Evans TRJ, Okusaka T, Glen H, Lubiniecki GM, Dutcus C, Smith AD, Okpara CE, Hussein Z, Hayato S, Tamai T, Makker V. Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies. Expert Rev Anticancer Ther 2022. [PMID: 35260027 DOI: 10.1080/14737140.2022.2039123] [Reference Citation Analysis]
17 Cavalieri S, Cosmai L, Genderini A, Nebuloni M, Tosoni A, Favales F, Pistillo P, Bergamini C, Bossi P, Licitra L, Locati LD, Alfieri S. Lenvatinib-induced renal failure: two first-time case reports and review of literature. Expert Opinion on Drug Metabolism & Toxicology 2018;14:379-85. [DOI: 10.1080/17425255.2018.1461839] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
18 Yamashige D, Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Okubo S, Muraishi N, Kajiwara A, Iritani S, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H. Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment. Oncology 2021;99:169-76. [PMID: 33207358 DOI: 10.1159/000510754] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Kudo M. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. Liver Cancer 2020;9:640-62. [PMID: 33442538 DOI: 10.1159/000511001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
20 Raoul JL, Gilabert M, Adhoute X, Edeline J. An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma. Expert Opin Pharmacother. 2017;18:1467-1476. [PMID: 28893090 DOI: 10.1080/14656566.2017.1378346] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
21 Taniguchi M, Mizuno S, Yoshikawa T, Fujinami N, Sugimoto M, Kobayashi S, Takahashi S, Konishi M, Gotohda N, Nakatsura T. Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis. Cancer Sci. 2020;111:2747-2759. [PMID: 32449239 DOI: 10.1111/cas.14497] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
22 Ding XX, Zhu QG, Zhang SM, Guan L, Li T, Zhang L, Wang SY, Ren WL, Chen XM, Zhao J, Lin S, Liu ZZ, Bai YX, He B, Zhang HQ. Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy. Oncotarget. 2017;8:55715-55730. [PMID: 28903454 DOI: 10.18632/oncotarget.18382] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 8.2] [Reference Citation Analysis]
23 Cidon EU. Systemic treatment of hepatocellular carcinoma: Past, present and future. World J Hepatol 2017; 9(18): 797-807 [PMID: 28706578 DOI: 10.4254/wjh.v9.i18.797] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 6.4] [Reference Citation Analysis]
24 Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Tanaka H, Tamai T, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group., HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma. Oncology 2019;97:277-85. [PMID: 31307035 DOI: 10.1159/000501281] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 10.7] [Reference Citation Analysis]
25 Capozzi M, De Divitiis C, Ottaiano A, von Arx C, Scala S, Tatangelo F, Delrio P, Tafuto S. Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment. Cancer Manag Res 2019;11:3847-60. [PMID: 31118801 DOI: 10.2147/CMAR.S188316] [Cited by in Crossref: 30] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
26 Personeni N, Pressiani T, Rimassa L. Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date. J Hepatocell Carcinoma 2019;6:31-9. [PMID: 30775342 DOI: 10.2147/JHC.S168953] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
27 Dika IE, Abou-Alfa GK. Treatment options after sorafenib failure in patients with hepatocellular carcinoma. Clin Mol Hepatol 2017;23:273-9. [PMID: 29151326 DOI: 10.3350/cmh.2017.0108] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
28 Hao Z, Wang P. Lenvatinib in Management of Solid Tumors. Oncologist 2020;25:e302-10. [PMID: 32043789 DOI: 10.1634/theoncologist.2019-0407] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
29 Hulin A, Stocco J, Bouattour M. Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma. Clin Pharmacokinet 2019;58:983-1014. [PMID: 31093928 DOI: 10.1007/s40262-019-00740-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
30 Zarour LR, Billingsley KG, Walker BS, Enestvedt CK, Orloff SL, Maynard E, Mayo SC. Hepatic resection of solitary HCC in the elderly: A unique disease in a growing population. Am J Surg 2019;217:899-905. [PMID: 30819401 DOI: 10.1016/j.amjsurg.2019.01.030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
31 Kudo M. A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib. Liver Cancer. 2017;6:177-184. [PMID: 28626729 DOI: 10.1159/000462153] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
32 Ikesue H, Yamamoto H, Hirabatake M, Hashida T, Chung H, Inokuma T, Muroi N. Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib. Biol Pharm Bull 2022;45:333-8. [PMID: 35228399 DOI: 10.1248/bpb.b21-00913] [Reference Citation Analysis]
33 Feng Y, Jiang W, Zhao W, Lu Z, Gu Y, Dong Y. miR-124 regulates liver cancer stem cells expansion and sorafenib resistance. Exp Cell Res 2020;394:112162. [PMID: 32640195 DOI: 10.1016/j.yexcr.2020.112162] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
34 Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599-616. [PMID: 30061739 DOI: 10.1038/s41571-018-0073-4] [Cited by in Crossref: 482] [Cited by in F6Publishing: 494] [Article Influence: 160.7] [Reference Citation Analysis]
35 Yu H, Bai Y, Xie X, Feng Y, Yang Y, Zhu Q. RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis. BMJ Open 2022;12:e052294. [DOI: 10.1136/bmjopen-2021-052294] [Reference Citation Analysis]
36 Kirino S, Tsuchiya K, Kurosaki M, Kaneko S, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Okada M, Wang W, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Izumi N. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. PLoS One 2020;15:e0231828. [PMID: 32310967 DOI: 10.1371/journal.pone.0231828] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
37 Zhu J, Yin T, Xu Y, Lu XJ. Therapeutics for advanced hepatocellular carcinoma: Recent advances, current dilemma, and future directions. J Cell Physiol. 2019;234:12122-12132. [PMID: 30644100 DOI: 10.1002/jcp.28048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
38 Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H, Furuse J. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Japanese Journal of Clinical Oncology 2018;48:103-14. [DOI: 10.1093/jjco/hyx180] [Cited by in Crossref: 78] [Cited by in F6Publishing: 79] [Article Influence: 15.6] [Reference Citation Analysis]
39 Zhang CH, Li M, Lin YP, Gao Q. Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes. Curr Gene Ther 2020;20:84-99. [PMID: 32600231 DOI: 10.2174/1566523220666200628014530] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Saito K, Fujii H, Kono K, Hirabayashi K, Yamatani S, Watanabe K, Goto S, Komatsu S, Fukumoto T, Nishi S. Changes in blood pressure during treatment with the tyrosine kinase inhibitor lenvatinib. Clin Kidney J 2021;14:325-31. [PMID: 33564435 DOI: 10.1093/ckj/sfaa137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Zhou XT, Ding J, Li HY, Zuo JL, Ge SY, Jia HL, Wu J. Hedgehog signalling mediates drug resistance through targeting TAP1 in hepatocellular carcinoma. J Cell Mol Med 2020;24:4298-311. [PMID: 32108992 DOI: 10.1111/jcmm.15090] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
42 Noda S, Iida H, Fujimoto T, Wakasugi Y, Yabuta N, Sudou M, Hira D, Tani M, Andoh A, Morita SY, Terada T. Exploratory analysis of target concentration of lenvatinib in the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 2021;88:281-8. [PMID: 33928425 DOI: 10.1007/s00280-021-04286-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Hirooka M, Ochi H, Hiraoka A, Koizumi Y, Matsuura B, Joko K, Michitaka K, Abe M, Hiasa Y. Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma. Intern Med 2019;58:791-5. [PMID: 30333428 DOI: 10.2169/internalmedicine.1874-18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
44 Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73. [PMID: 29433850 DOI: 10.1016/S0140-6736(18)30207-1] [Cited by in Crossref: 1304] [Cited by in F6Publishing: 854] [Article Influence: 326.0] [Reference Citation Analysis]
45 Yamaoka K, Kodama K, Hiramatsu A, Ando Y, Kosaka Y, Suehiro Y, Fujii Y, Uchikawa S, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Imamura M, Takahashi S, Chayama K, Aikata H. Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2021;36:1685-93. [PMID: 33326154 DOI: 10.1111/jgh.15377] [Reference Citation Analysis]
46 He XX, Shi LL, Qiu MJ, Li QT, Wang MM, Xiong ZF, Yang SL. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families. Biochem Biophys Res Commun 2018;504:878-84. [PMID: 30219235 DOI: 10.1016/j.bbrc.2018.08.203] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
47 Wan S, Nie Y, Zhu X. Development of a prognostic scoring model for predicting the survival of elderly patients with hepatocellular carcinoma. PeerJ 2020;8:e8497. [PMID: 32117619 DOI: 10.7717/peerj.8497] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
48 Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treat Rev. 2018;68:16-24. [PMID: 29783126 DOI: 10.1016/j.ctrv.2018.05.006] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 17.0] [Reference Citation Analysis]
49 Curry L, Limaye W, Ramjeesingh R. Spontaneous regression of metastatic hepatocellular carcinoma following 3 weeks of lenvatinib. BMJ Case Rep 2022;15:e247212. [PMID: 35140091 DOI: 10.1136/bcr-2021-247212] [Reference Citation Analysis]
50 Shomura M, Okabe H, Sato E, Fukai K, Shiraishi K, Hirose S, Tsuruya K, Arase Y, Anzai K, Kagawa T. Hypothyroidism is a Predictive Factor for Better Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Undergoing Lenvatinib Therapy. Cancers (Basel) 2020;12:E3078. [PMID: 33105621 DOI: 10.3390/cancers12113078] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
51 Sadeghi S, Bejjani A, Finn RS. Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma. Surg Oncol Clin N Am 2019;28:695-715. [PMID: 31472914 DOI: 10.1016/j.soc.2019.06.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Eso Y, Nakano S, Mishima M, Arasawa S, Iguchi E, Takeda H, Takai A, Takahashi K, Taura K, Seno H. Mac-2 binding protein glycosylation isomer predicts tolerability and clinical outcome of lenvatinib therapy for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2021;28:498-507. [PMID: 33787071 DOI: 10.1002/jhbp.954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
53 Ma G, Du X, Zhu J, Xu F, Yu H, Li J. Multi-functionalized dendrimers for targeted co-delivery of sorafenib and paclitaxel in liver cancers. Journal of Drug Delivery Science and Technology 2021;63:102493. [DOI: 10.1016/j.jddst.2021.102493] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
54 Shi JJ, Dang SS. Recent advances in molecular targeted therapy of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2018; 26(34): 2008-2017 [DOI: 10.11569/wcjd.v26.i34.2008] [Reference Citation Analysis]
55 Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Kasuya K, Sano T, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H. Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis. Liver Cancer 2020;9:275-92. [PMID: 32647631 DOI: 10.1159/000505190] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
56 Cetin M, Odabas G, Douglas LR, Duriez PJ, Balcik-Ercin P, Yalim-Camci I, Sayan AE, Yagci T. ROR1 Expression and Its Functional Significance in Hepatocellular Carcinoma Cells. Cells 2019;8:E210. [PMID: 30832318 DOI: 10.3390/cells8030210] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
57 Mo DC, Luo PH, Huang SX, Wang HL, Huang JF. Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review. Int Immunopharmacol 2021;91:107281. [PMID: 33338862 DOI: 10.1016/j.intimp.2020.107281] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
58 Decraecker M, Toulouse C, Blanc JF. Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib. Cancers (Basel) 2021;13:6310. [PMID: 34944930 DOI: 10.3390/cancers13246310] [Reference Citation Analysis]
59 Sato A, Imai Y, Uchiya H, Uchida Y, Nakazawa M, Sugawara K, Nakayama N, Mochida S. Two Cases of Intraabdominal Bleeding Caused by Hepatocellular Carcinoma Rupture Soon after the Initiation of Chemotherapy with Lenvatinib. Intern Med . [DOI: 10.2169/internalmedicine.8733-21] [Reference Citation Analysis]
60 Mody K, Abou-Alfa GK. Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape. Curr Treat Options Oncol. 2019;20:3. [PMID: 30635732 DOI: 10.1007/s11864-019-0601-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
61 Duan J, Wu Y, Liu J, Zhang J, Fu Z, Feng T, Liu M, Han J, Li Z, Chen S. Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine.J Hepatocell Carcinoma. 2019;6:151-166. [PMID: 31696097 DOI: 10.2147/JHC.S224849] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
62 Kang X, Lin Z, Xu M, Pan J, Wang ZW. Deciphering role of FGFR signalling pathway in pancreatic cancer. Cell Prolif 2019;52:e12605. [PMID: 30945363 DOI: 10.1111/cpr.12605] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
63 B Peters ML, Miksad RA. Cabozantinib in the treatment of hepatocellular carcinoma. Future Oncology 2017;13:1915-29. [DOI: 10.2217/fon-2017-0169] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
64 Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Mamontov K, Meyer T, Kubota T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol 2020;38:2960-70. [PMID: 32716739 DOI: 10.1200/JCO.20.00808] [Cited by in Crossref: 100] [Cited by in F6Publishing: 100] [Article Influence: 50.0] [Reference Citation Analysis]
65 Galati G, Massimo Vainieri AF, Maria Fulgenzi CA, Di Donato S, Silletta M, Gallo P, Onorato A, Vespasiani-Gentilucci U, Picardi A. Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis. Curr Drug Metab 2020;21:866-84. [PMID: 32957880 DOI: 10.2174/1389200221999200918141239] [Reference Citation Analysis]
66 Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF, Nault JC, Avila MA. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. Gut 2018;67:380-8. [PMID: 29150490 DOI: 10.1136/gutjnl-2017-315068] [Cited by in Crossref: 92] [Cited by in F6Publishing: 88] [Article Influence: 23.0] [Reference Citation Analysis]
67 Rimassa L, Pressiani T, Merle P. Systemic Treatment Options in Hepatocellular Carcinoma. Liver Cancer. 2019;8:427-446. [PMID: 31799201 DOI: 10.1159/000499765] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
68 Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Fujisawa K, Matsumoto T, Hidaka I, Marumoto Y, Ishikawa T, Yamamoto N, Suehiro Y, Takami T, Sakaida I. Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy. World J Hepatol 2018; 10(9): 571-584 [PMID: 30310535 DOI: 10.4254/wjh.v10.i9.571] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
69 Bouattour M, Mehta N, He AR, Cohen EI, Nault JC. Systemic Treatment for Advanced Hepatocellular Carcinoma. Liver Cancer. 2019;8:341-358. [PMID: 31768344 DOI: 10.1159/000496439] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 11.0] [Reference Citation Analysis]
70 Hida T, Velcheti V, Reckamp KL, Nokihara H, Sachdev P, Kubota T, Nakada T, Dutcus CE, Ren M, Tamura T. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma. Lung Cancer 2019;138:124-30. [DOI: 10.1016/j.lungcan.2019.09.011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 9.7] [Reference Citation Analysis]
71 Zschäbitz S, Grüllich C. Lenvantinib: A Tyrosine Kinase Inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET. Recent Results Cancer Res 2018;211:187-98. [PMID: 30069768 DOI: 10.1007/978-3-319-91442-8_13] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
72 Ueno Y. New treatment-induced adverse effects we need to learn as modern hepatologists. Hepatol Int 2019;13:391-4. [PMID: 31016539 DOI: 10.1007/s12072-019-09947-2] [Reference Citation Analysis]
73 Eso Y, Nakano S, Mishima M, Arasawa S, Iguchi E, Nakamura F, Takeda H, Takai A, Takahashi K, Taura K, Seno H. Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma. Cancers (Basel). 2019;12:49. [PMID: 31877859 DOI: 10.3390/cancers12010049] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
74 Sasaki R, Fukushima M, Haraguchi M, Miuma S, Miyaaki H, Hidaka M, Eguchi S, Matsuo S, Tajima K, Matsuzaki T, Hashimoto S, Ooba K, Kugiyama Y, Yatsuhashi H, Motoyoshi Y, Shigeno M, Kinoshita N, Nakao K. Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings. Cancers (Basel). 2019;11:1769. [PMID: 31717674 DOI: 10.3390/cancers11111769] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
75 Kudo M. Systemic Therapy for Hepatocellular Carcinoma: Latest Advances. Cancers (Basel). 2018;10. [PMID: 30380773 DOI: 10.3390/cancers10110412] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 19.5] [Reference Citation Analysis]
76 Kim BH, Yu SJ, Kang W, Cho SB, Park SY, Kim SU, Kim DY. Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma. J Gastroenterol Hepatol 2021. [PMID: 34725855 DOI: 10.1111/jgh.15727] [Reference Citation Analysis]
77 Long HY, Huang TY, Xie XY, Long JT, Liu BX. Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis. World J Clin Cases 2021; 9(21): 5754-5768 [PMID: 34368295 DOI: 10.12998/wjcc.v9.i21.5754] [Reference Citation Analysis]
78 Neureiter D, Stintzing S, Kiesslich T, Ocker M. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. World J Gastroenterol 2019; 25(25): 3136-3150 [PMID: 31333307 DOI: 10.3748/wjg.v25.i25.3136] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
79 Nishida N, Kudo M. Immune checkpoint blockade for the treatment of human hepatocellular carcinoma. Hepatol Res 2018;48:622-34. [PMID: 29734514 DOI: 10.1111/hepr.13191] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
80 Yanagihara T, Matsumoto K, Yoneda R, Egashira A, Mannoji H, Watanabe H, Hanaoka K, Nakayama Y, Ogo N, Inutsuka Y, Asoh T, Kohashi K, Kinoshita I, Oda Y, Maeyama T. Lenvatinib for poorly differentiated carcinoma of the anterior mediastinum. Respir Med Case Rep 2021;33:101477. [PMID: 34401310 DOI: 10.1016/j.rmcr.2021.101477] [Reference Citation Analysis]
81 Uojima H, Chuma M, Tanaka Y, Hidaka H, Nakazawa T, Iwabuchi S, Kobayashi S, Hattori N, Ogushi K, Morimoto M, Kagawa T, Tanaka K, Kako M, Koizumi W. Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib. Liver Cancer 2020;9:193-206. [PMID: 32399433 DOI: 10.1159/000504604] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
82 Tateishi R. The Era of the Hepatic Oncologist. Liver Cancer 2020;9:378-81. [PMID: 32999865 DOI: 10.1159/000508342] [Reference Citation Analysis]
83 Raoul JL, Frenel JS, Raimbourg J, Gilabert M. Current options and future possibilities for the systemic treatment of hepatocellular carcinoma. Hepat Oncol 2019;6:HEP11. [PMID: 31244990 DOI: 10.2217/hep-2019-0001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
84 Winters AC, Bedier F, Saab S. Management of Side Effects of Systemic Therapies for Hepatocellular Carcinoma: Guide for the Hepatologist. Clin Liver Dis 2020;24:755-69. [PMID: 33012457 DOI: 10.1016/j.cld.2020.07.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Wang N, Wang S, Li MY, Hu BG, Liu LP, Yang SL, Yang S, Gong Z, Lai PBS, Chen GG. Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies. Ther Adv Med Oncol. 2018;10:1758835918816287. [PMID: 30622654 DOI: 10.1177/1758835918816287] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 10.5] [Reference Citation Analysis]
86 Li X, Li Y, Lu W, Chen M, Ye W, Zhang D. The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis. Cells 2019;8:E1602. [PMID: 31835465 DOI: 10.3390/cells8121602] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
87 Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Eguchi S, Yamashita T, Kudo M. Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan. Liver Cancer 2019;8:403-11. [PMID: 31768348 DOI: 10.1159/000495944] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
88 Kudo M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World J Gastroenterol 2019; 25(7): 789-807 [PMID: 30809080 DOI: 10.3748/wjg.v25.i7.789] [Cited by in CrossRef: 77] [Cited by in F6Publishing: 70] [Article Influence: 25.7] [Reference Citation Analysis]
89 da Fonseca LG, Reig M, Bruix J. Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma. Clin Liver Dis 2020;24:719-37. [PMID: 33012455 DOI: 10.1016/j.cld.2020.07.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
90 Ono A, Aikata H, Yamauchi M, Kodama K, Ohishi W, Kishi T, Ohya K, Teraoka Y, Osawa M, Fujino H, Nakahara T, Murakami E, Miki D, Kawaoka T, Abe-Chayama H, Zhang P, Liu S, Makokha GN, Tsuge M, Imamura M, Hayes CN, Chayama K. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib. Ther Adv Med Oncol 2020;12:1758835920922051. [PMID: 32547646 DOI: 10.1177/1758835920922051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
91 Suyama K, Iwase H. Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers. Cancer Control 2018;25:1073274818789361. [PMID: 30032643 DOI: 10.1177/1073274818789361] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
92 Contratto M, Wu J. Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma. World J Gastrointest Oncol 2018; 10(5): 108-114 [PMID: 29770170 DOI: 10.4251/wjgo.v10.i5.108] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
93 Takeda H, Nishijima N, Nasu A, Komekado H, Kita R, Kimura T, Kudo M, Osaki Y. Long-term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion. Hepatol Res. 2019;49:594-599. [PMID: 30499247 DOI: 10.1111/hepr.13294] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
94 Raybould AL, Sanoff H. Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date. J Hepatocell Carcinoma 2020;7:133-42. [PMID: 32984090 DOI: 10.2147/JHC.S224938] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
95 Pinter M, Peck-Radosavljevic M. Review article: systemic treatment of hepatocellular carcinoma. Aliment Pharmacol Ther 2018;48:598-609. [PMID: 30039640 DOI: 10.1111/apt.14913] [Cited by in Crossref: 63] [Cited by in F6Publishing: 69] [Article Influence: 15.8] [Reference Citation Analysis]
96 Koroki K, Kanogawa N, Maruta S, Ogasawara S, Iino Y, Obu M, Okubo T, Itokawa N, Maeda T, Inoue M, Haga Y, Seki A, Okabe S, Koma Y, Azemoto R, Atsukawa M, Itobayashi E, Ito K, Sugiura N, Mizumoto H, Unozawa H, Iwanaga T, Sakuma T, Fujita N, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Saito T, Kondo T, Suzuki E, Ooka Y, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Kato N. Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer 2021;10:473-84. [PMID: 34721509 DOI: 10.1159/000515552] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Nakano M, Kuromatsu R, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis. Hepatol Commun 2020;4:1218-28. [PMID: 32766480 DOI: 10.1002/hep4.1535] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
98 Alqahtani SA, Colombo MG. Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma . World J Gastrointest Oncol 2021; 13(12): 2038-2049 [DOI: 10.4251/wjgo.v13.i12.2038] [Reference Citation Analysis]
99 Cardoso E, Guidi M, Blanchet B, Schneider MP, Decosterd LA, Buclin T, Csajka C, Widmer N. Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review. Ther Drug Monit 2020;42:33-44. [PMID: 31479043 DOI: 10.1097/FTD.0000000000000699] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
100 Hatanaka T, Naganuma A, Kakizaki S. Lenvatinib for Hepatocellular Carcinoma: A Literature Review. Pharmaceuticals (Basel) 2021;14:36. [PMID: 33418941 DOI: 10.3390/ph14010036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Obi S, Sato T, Sato S, Kanda M, Tokudome Y, Kojima Y, Suzuki Y, Hosoda K, Kawai T, Kondo Y, Isomura Y, Ohyama H, Nakagomi K, Ashizawa H, Miura Y, Amano H, Mochizuki H, Omata M. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting. Hepatol Int. 2019;13:199-204. [PMID: 30671808 DOI: 10.1007/s12072-019-09929-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
102 Kudo M, Ueshima K, Chan S, Minami T, Chishina H, Aoki T, Takita M, Hagiwara S, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Wada Y, Ikeda M, Ishii H, Izumi N, Nishida N. Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study. Cancers (Basel). 2019;11. [PMID: 31370183 DOI: 10.3390/cancers11081084] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 15.0] [Reference Citation Analysis]
103 Suoh M, Fujii H, Nagata Y, Kotani K, Hagihara A, Enomoto M, Tamori A, Inaba M, Kawada N. Destructive thyroiditis presenting as thyrotoxicosis followed by hypothyroidism during lenvatinib therapy for hepatocellular carcinoma. Clin J Gastroenterol 2020;13:860-6. [DOI: 10.1007/s12328-020-01107-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Hata K, Suetsugu K, Egashira N, Makihara Y, Itoh S, Yoshizumi T, Tanaka M, Kohjima M, Watanabe H, Masuda S, Ieiri I. Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma. Cancer Chemother Pharmacol 2020;86:803-13. [PMID: 33095285 DOI: 10.1007/s00280-020-04178-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
105 Ogasawara S, Ooka Y, Kato N. Weight-based dosing of lenvatinib for advanced hepatocellular carcinoma. Hepatobiliary Surg Nutr 2020;9:253-4. [PMID: 32355695 DOI: 10.21037/hbsn.2019.09.21] [Reference Citation Analysis]
106 Chon YE, Park H, Hyun HK, Ha Y, Kim MN, Kim BK, Lee JH, Kim SU, Kim DY, Ahn SH, Hwang SG, Han KH, Rim KS, Park JY. Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Cancers (Basel) 2019;11:E509. [PMID: 30974843 DOI: 10.3390/cancers11040509] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
107 Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Itobayashi E, Shimada N, Tajiri K, Tsuji K, Ishikawa T, Ochi H, Hirooka M, Tsutsui A, Shibata H, Tada T, Toyoda H, Nouso K, Joko K, Hiasa Y, Michitaka K; Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis. Hepatol Res 2019;49:111-7. [PMID: 30144256 DOI: 10.1111/hepr.13243] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 11.0] [Reference Citation Analysis]
108 Chen S, Cao Q, Wen W, Wang H. Targeted therapy for hepatocellular carcinoma: Challenges and opportunities. Cancer Lett. 2019;460:1-9. [PMID: 31207320 DOI: 10.1016/j.canlet.2019.114428] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 16.7] [Reference Citation Analysis]
109 Endo M, Honda K, Saito T, Shiraiwa K, Sueshige Y, Tokumaru T, Iwao M, Tokoro M, Arakawa M, Tanaka R, Tatsuta R, Seike M, Itoh H, Murakami K. Maximum Plasma Concentration of Lenvatinib Is Useful for Predicting Thrombocytopenia in Patients Treated for Hepatocellular Carcinoma. World J Oncol 2021;12:165-72. [PMID: 34804279 DOI: 10.14740/wjon1399] [Reference Citation Analysis]
110 Al-salama ZT, Syed YY, Scott LJ. Lenvatinib: A Review in Hepatocellular Carcinoma. Drugs 2019;79:665-74. [DOI: 10.1007/s40265-019-01116-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
111 Deng H, Kan A, Lyu N, He M, Huang X, Qiao S, Li S, Lu W, Xie Q, Chen H, Lai J, Chen Q, Jiang X, Liu S, Zhang Z, Zhao M. Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma. J Immunother Cancer 2021;9:e002305. [PMID: 34168004 DOI: 10.1136/jitc-2020-002305] [Reference Citation Analysis]
112 Hatanaka T, Kakizaki S, Nagashima T, Namikawa M, Tojima H, Shimada Y, Takizawa D, Naganuma A, Arai H, Sato K, Harimoto N, Shirabe K, Uraoka T. Analyses of objective response rate, progression-free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study. Hepatol Res. 2020;50:382-395. [PMID: 31760660 DOI: 10.1111/hepr.13460] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
113 Piñero F, Tanno M, Aballay Soteras G, Tisi Baña M, Dirchwolf M, Fassio E, Ruf A, Mengarelli S, Borzi S, Fernández N, Ridruejo E, Descalzi V, Anders M, Mazzolini G, Reggiardo V, Marciano S, Perazzo F, Spina JC, McCormack L, Maraschio M, Lagues C, Gadano A, Villamil F, Silva M, Cairo F, Ameigeiras B; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Ann Hepatol 2020;19:546-69. [PMID: 32593747 DOI: 10.1016/j.aohep.2020.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
114 Bakrania A, Zheng G, Bhat M. Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment. Pharmaceutics 2021;14:41. [PMID: 35056937 DOI: 10.3390/pharmaceutics14010041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
115 da Motta Girardi D, Correa TS, Crosara Teixeira M, Dos Santos Fernandes G. Hepatocellular Carcinoma: Review of Targeted and Immune Therapies. J Gastrointest Canc 2018;49:227-36. [DOI: 10.1007/s12029-018-0121-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
116 Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K; On behalf of the Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma. Oncology 2019;97:334-40. [PMID: 31466068 DOI: 10.1159/000502095] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
117 Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Okubo S, Tominaga L, Kajiwara A, Kasuya K, Iritani S, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kozuka T, Kumada H. Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma. Liver Cancer 2020;9:756-70. [PMID: 33442544 DOI: 10.1159/000510299] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
118 Hsu SJ, Xu X, Chen MP, Zhao ZY, Wang Y, Yin X, Zhang L, Ge NL, Chen Y, Wang YH, Luo JF, Ren ZG, Chen RX. Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization. Acad Radiol 2021;28 Suppl 1:S157-66. [PMID: 33653656 DOI: 10.1016/j.acra.2021.01.024] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Meyer T. Treatment of advanced hepatocellular carcinoma: beyond sorafenib. Lancet Gastroenterol Hepatol. 2018;3:218-220. [PMID: 29533189 DOI: 10.1016/s2468-1253(17)30255-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
120 Huang D, Fan Q, Liu Z, Zhang S, Huang W, Li H, Liang C, Sun F. An Epitope on EGFR Loading Catastrophic Internalization Serve as a Novel Oncotarget for Hepatocellular Carcinoma Therapy. Cancers (Basel) 2020;12:E456. [PMID: 32079107 DOI: 10.3390/cancers12020456] [Reference Citation Analysis]
121 Wu H, Ding X, Zhang Y, Li W, Chen J. Incidence and risk of hypertension with lenvatinib in treatment of solid tumors: An updated systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2022. [PMID: 35538636 DOI: 10.1111/jch.14463] [Reference Citation Analysis]
122 Koulouris A, Tsagkaris C, Spyrou V, Pappa E, Troullinou A, Nikolaou M. Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options. J Hepatocell Carcinoma 2021;8:387-401. [PMID: 34012929 DOI: 10.2147/JHC.S300182] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
123 Gu M, Toh TB, Hooi L, Lim JJ, Zhang X, Chow EK. Nanodiamond-Mediated Delivery of a G9a Inhibitor for Hepatocellular Carcinoma Therapy. ACS Appl Mater Interfaces 2019;11:45427-41. [PMID: 31718136 DOI: 10.1021/acsami.9b16323] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
124 Yamamura K, Beppu T. Conversion surgery for hepatocellular carcinoma after multidisciplinary treatment including lenvatinib. Hepatol Res 2021;51:1029-30. [PMID: 34596312 DOI: 10.1111/hepr.13691] [Reference Citation Analysis]
125 Kudo M. Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma. Liver Cancer 2018;7:1-19. [PMID: 29662829 DOI: 10.1159/000487148] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 10.3] [Reference Citation Analysis]
126 Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Kasuya K, Sano T, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H. 18F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to Lenvatinib. Liver Cancer 2020;9:84-92. [PMID: 32071912 DOI: 10.1159/000503577] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
127 Ji L, Lin Z, Wan Z, Xia S, Jiang S, Cen D, Cai L, Xu J, Cai X. miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR. Cell Death Dis 2020;11:250. [PMID: 32313144 DOI: 10.1038/s41419-020-2413-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
128 Lee A, Lee FC. Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check. Front Med 2020;14:273-83. [PMID: 31863306 DOI: 10.1007/s11684-019-0728-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
129 Galun D, Mijac D, Filipovic A, Bogdanovic A, Zivanovic M, Masulovic D. Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. JPM 2022;12:149. [DOI: 10.3390/jpm12020149] [Reference Citation Analysis]
130 Okusaka T, Ikeda K, Kudo M, Finn R, Qin S, Han KH, Cheng AL, Piscaglia F, Kobayashi M, Sung M, Chen M, Wyrwicz L, Yoon JH, Ren Z, Mody K, Dutcus C, Tamai T, Ren M, Hayato S, Kumada H. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. J Gastroenterol 2021;56:570-80. [PMID: 33948712 DOI: 10.1007/s00535-021-01785-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
131 Cheon J, Chon HJ, Bang Y, Park NH, Shin JW, Kim KM, Lee HC, Lee J, Yoo C, Ryoo BY. Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis. Liver Cancer 2020;9:613-24. [PMID: 33083284 DOI: 10.1159/000508901] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
132 Wang C, Jin H, Gao D, Lieftink C, Evers B, Jin G, Xue Z, Wang L, Beijersbergen RL, Qin W, Bernards R. Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer. J Hepatol 2018;69:1057-65. [PMID: 30030148 DOI: 10.1016/j.jhep.2018.07.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 8.3] [Reference Citation Analysis]
133 Jindal A, Thadi A, Shailubhai K. Hepatocellular Carcinoma: Etiology and Current and Future Drugs. J Clin Exp Hepatol 2019;9:221-32. [PMID: 31024205 DOI: 10.1016/j.jceh.2019.01.004] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 20.7] [Reference Citation Analysis]
134 Sato J, Satouchi M, Itoh S, Okuma Y, Niho S, Mizugaki H, Murakami H, Fujisaka Y, Kozuki T, Nakamura K, Nagasaka Y, Kawasaki M, Yamada T, Machida R, Kuchiba A, Ohe Y, Yamamoto N. Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. Lancet Oncol 2020;21:843-50. [PMID: 32502444 DOI: 10.1016/S1470-2045(20)30162-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
135 Zhao Y, Zhang YN, Wang KT, Chen L. Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy. Biochim Biophys Acta Rev Cancer 2020;1874:188391. [PMID: 32659252 DOI: 10.1016/j.bbcan.2020.188391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
136 Casadei Gardini A, Puzzoni M, Montagnani F, Marisi G, Tamburini E, Cucchetti A, Solaini L, Foschi FG, Conti F, Ercolani G, Cascinu S, Scartozzi M. Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials. Onco Targets Ther. 2019;12:2981-2988. [PMID: 31118665 DOI: 10.2147/ott.s192572] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
137 Eso Y, Marusawa H. Novel approaches for molecular targeted therapy against hepatocellular carcinoma: Molecular targeted therapy for liver cancer. Hepatol Res 2018;48:597-607. [DOI: 10.1111/hepr.13181] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 9.0] [Reference Citation Analysis]
138 Xie WJ, Zhang S, Su L, Li YH, Zhang X, Ran YG. The efficacy and safety of lenvatinib in the treatment of solid tumors: an up-to-date meta-analysis. Future Oncol 2021;17:745-54. [PMID: 33401983 DOI: 10.2217/fon-2020-0327] [Reference Citation Analysis]
139 Zhang W, Hu B, Han J, Wang Z, Ma G, Ye H, Yuan J, Cao J, Zhang Z, Shi J, Chen M, Wang X, Xu Y, Cheng Y, Tian L, Wang H, Lu S. Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients. Front Oncol 2021;11:747950. [PMID: 34737958 DOI: 10.3389/fonc.2021.747950] [Reference Citation Analysis]
140 Lee SJ, Lim HY. Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists. Expert Opinion on Emerging Drugs 2017;22:191-200. [DOI: 10.1080/14728214.2017.1330886] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
141 Akazawa Y, Suzuki T, Yoshikawa T, Mizuno S, Nakamoto Y, Nakatsura T. Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma. World J Meta-Anal 2019; 7(3): 80-95 [DOI: 10.13105/wjma.v7.i3.80] [Reference Citation Analysis]
142 Okubo H, Ando H, Ishizuka K, Morishige JI, Ikejima K, Shiina S, Nagahara A. Impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of lenvatinib in patients with hepatocellular carcinoma. J Pharmacol Sci 2022;148:6-13. [PMID: 34924131 DOI: 10.1016/j.jphs.2021.08.011] [Reference Citation Analysis]
143 Niu M, Yi M, Li N, Wu K, Wu K. Advances of Targeted Therapy for Hepatocellular Carcinoma. Front Oncol 2021;11:719896. [PMID: 34381735 DOI: 10.3389/fonc.2021.719896] [Reference Citation Analysis]
144 Han B, Ding H, Zhao S, Zhang Y, Wang J, Zhang Y, Gu J. Potential Role of Adjuvant Lenvatinib in Improving Disease-Free Survival for Patients With High-Risk Hepatitis B Virus-Related Hepatocellular Carcinoma Following Liver Transplantation: A Retrospective, Case Control Study. Front Oncol 2020;10:562103. [PMID: 33365268 DOI: 10.3389/fonc.2020.562103] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
145 Rinninella E, Cerrito L, Spinelli I, Cintoni M, Mele MC, Pompili M, Gasbarrini A. Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives. J Clin Transl Hepatol 2017;5:235-48. [PMID: 28936405 DOI: 10.14218/JCTH.2017.00002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
146 Dong D, Shi JY, Shang X, Liu B, Xu WL, Cui GZ, Wang NY. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib: A retrospective analysis. Medicine (Baltimore) 2022;101:e28680. [PMID: 35119010 DOI: 10.1097/MD.0000000000028680] [Reference Citation Analysis]
147 Pillai A, Ahn J, Kulik L. Integrating Genomics Into Clinical Practice in Hepatocellular Carcinoma: The Challenges Ahead. Am J Gastroenterol 2020;115:1960-9. [PMID: 33038134 DOI: 10.14309/ajg.0000000000000843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
148 Guo T, Liu P, Yang J, Wu P, Chen B, Liu Z, Li Z. Evaluation of Targeted Agents for Advanced and Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis. J Cancer 2019;10:4671-8. [PMID: 31528232 DOI: 10.7150/jca.32828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
149 Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Atsukawa M, Itobayashi E, Tsuji K, Tajiri K, Hirooka M, Shimada N, Shibata H, Ishikawa T, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Itokawa N, Imai M, Joko K, Hiasa Y, Michitaka K; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis. Cancer Med 2019;8:137-46. [PMID: 30575325 DOI: 10.1002/cam4.1909] [Cited by in Crossref: 81] [Cited by in F6Publishing: 66] [Article Influence: 20.3] [Reference Citation Analysis]
150 Nishida N, Kudo M. Liver damage related to immune checkpoint inhibitors. Hepatol Int. 2019;13:248-252. [PMID: 30607787 DOI: 10.1007/s12072-018-9921-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
151 Ishihara K. A Case of Multiple Intratumoral Hemorrhage and Rupture of Hepatocellular Carcinoma after Starting Lenvatinib. Case Reports Hepatol 2020;2020:6659388. [PMID: 33381332 DOI: 10.1155/2020/6659388] [Reference Citation Analysis]
152 Piñero F, Thompson M, Marín JI, Silva M. Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients? World J Transplant 2020; 10(11): 297-306 [PMID: 33312891 DOI: 10.5500/wjt.v10.i11.297] [Cited by in CrossRef: 2] [Article Influence: 1.0] [Reference Citation Analysis]
153 Zhou RS, Wang XW, Sun QF, Ye ZJ, Liu JW, Zhou DH, Tang Y. Anticancer Effects of Emodin on HepG2 Cell: Evidence from Bioinformatic Analysis. Biomed Res Int 2019;2019:3065818. [PMID: 31236404 DOI: 10.1155/2019/3065818] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
154 Ikeda M, Kobayashi M, Tahara M, Kaneko S. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib. Expert Opinion on Drug Safety 2018;17:1095-105. [DOI: 10.1080/14740338.2018.1530212] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
155 Hasan I, Loho IM, Setiawan PB, Djumhana A, Purnomo HD, Siregar L, Gani RA, Sulaiman AS, Lesmana CRA. Indonesian consensus on systemic therapies for hepatocellular carcinoma. Asia Pac J Clin Oncol 2022. [PMID: 35599455 DOI: 10.1111/ajco.13768] [Reference Citation Analysis]
156 Spallanzani A, Orsi G, Andrikou K, Gelsomino F, Rimini M, Riggi L, Cascinu S. Lenvatinib as a therapy for unresectable hepatocellular carcinoma. Expert Rev Anticancer Ther. 2018;18:1069-1076. [PMID: 30220234 DOI: 10.1080/14737140.2018.1524297] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
157 Goh MJ, Oh JH, Park Y, Kim J, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea. Liver Cancer 2021;10:52-62. [PMID: 33708639 DOI: 10.1159/000512239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
158 Chen R, Li Q, Xu S, Ye C, Tian T, Jiang Q, Shan J, Ruan J. Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment. Cancer Cell Int 2022;22:73. [PMID: 35148789 DOI: 10.1186/s12935-021-02435-4] [Reference Citation Analysis]
159 Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis. Cancer Med 2019;8:3719-28. [PMID: 31127698 DOI: 10.1002/cam4.2241] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 22.3] [Reference Citation Analysis]
160 Ronnebaum S, Aly A, Patel D, Benavente F, Rueda JD. Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma. Hepat Oncol 2022;9:HEP41. [PMID: 34765109 DOI: 10.2217/hep-2021-0003] [Reference Citation Analysis]
161 Yang F, Deng K, Zheng H, Liu Z, Zheng Y. Progress of targeted and immunotherapy for hepatocellular carcinoma and the application of next-generation sequencing. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100677] [Reference Citation Analysis]
162 Liu G, Chen T, Ding Z, Wang Y, Wei Y, Wei X. Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment. Cell Prolif 2021;54:e13009. [PMID: 33655556 DOI: 10.1111/cpr.13009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
163 Nigro O, Chini C, Proserpio I. Molecularly targeted therapy for advanced gastrointestinal noncolorectal cancer treatment: how to choose? Past, present, future. Anticancer Drugs 2021;32:593-601. [PMID: 33929995 DOI: 10.1097/CAD.0000000000001071] [Reference Citation Analysis]
164 Kuzuya T, Ishigami M, Ito T, Ishizu Y, Honda T, Ishikawa T, Fujishiro M. Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma. Hepatol Res 2020;50:374-81. [DOI: 10.1111/hepr.13452] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
165 Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther 2020;5:146. [PMID: 32782275 DOI: 10.1038/s41392-020-00264-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 11.5] [Reference Citation Analysis]
166 Bullock AJ. Gastrointestinal Tract Malignancies: Obstacles and Advancements. Clinical Therapeutics 2017;39:2122-4. [DOI: 10.1016/j.clinthera.2017.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
167 Piñero F, Silva M, Iavarone M. Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors. World J Gastroenterol 2020; 26(16): 1888-1900 [PMID: 32390700 DOI: 10.3748/wjg.v26.i16.1888] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
168 Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, Inaba Y, Kuromatsu R, Kobayashi M, Okusaka T, Tamai T, Kitamura C, Saito K, Haruna K, Okita K, Kumada H. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol 2020;55:113-22. [PMID: 31720835 DOI: 10.1007/s00535-019-01642-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 34] [Article Influence: 9.3] [Reference Citation Analysis]
169 Tamai T, Hayato S, Hojo S, Suzuki T, Okusaka T, Ikeda K, Kumada H. Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses. J Clin Pharmacol. 2017;57:1138-1147. [PMID: 28561918 DOI: 10.1002/jcph.917] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 8.2] [Reference Citation Analysis]
170 Kudo M. Lenvatinib in Advanced Hepatocellular Carcinoma. Liver Cancer. 2017;6:253-263. [PMID: 29234629 DOI: 10.1159/000479573] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]